PRRT

In May, 2017,  Dr. Tom Hope from UCSF spoke to NorCal Carcinet with an update on PRRT.

1/26/18 - Advanced Accelerator Applications (AAA) Receives FDA Approval of Lutetium (177Lu) Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine
AAA announced that the Federal Drug Administration (FDA) has approved the new drug application (NDA) for LUTATHERA® (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Click here to read the company press release or here to read the full prescribing information.

 NorCal CarciNET President, Josh Mailman discusses this with Drs. Hope, Kunz, Strossberg and Liu on Facebook. Click here to view

Advanced Accelerator Applications (AAA) Receives European Approval of Lutetium (177Lu) Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine

AAA announced on September 29, 2017 that the European Commission (EC) has approved the marketing authorization of lutetium (177Lu) oxodotreotide* (Lutathera®) for “the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults.” This approval allows for the marketing of lutetium (177Lu) oxodotreotide* (Lutathera®) in all 28 European Union member states, as well as Iceland, Norway and Liechtenstein. A New Drug Application is currently under review by the US Food and Drug Administration. The Prescription Drug User Fee Act (PDUFA) action date is January 26, 2018. Click here to read the company press release or here to read the EU approval.

NorCal CarciNET Community has been involved in producing two PRTT webinars in 2020.

The first for LACNETS will give you a general understanding of how PRRT works as given in United States

This video features:
Lindy Gardner, BSN, RN, Lead Nurse, PRRT Program, UCLA Health
Thomas Hope, MD, Assistant Professor, Abdominal Imaging and Nuclear Medicine, UCSF
Josh Mailman, MBA, President, NorCal CarciNET Community
Boris Naraev, MD, PhD, Lead, Neuroendocrine Oncology Program, Banner Health

The second video is a more in-depth look at PRRT with 7 experts from around the world and was done in conjunction with the Society of Nuclear Medicine and Molecular Imaging.

This video features:

Jaydira Del Rivero, MD, National Cancer Institute Center for Cancer Research, Bethesda, MD
Ebrahim Delpassand, MD, Excel Diagnostics and Nuclear Oncology Center, Houston, TX
Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Tom Hope, University of California San Francisco, San Francisco, CA
Josh Mailman, NorCal CarciNET, San Francisco, CA
Sukhmani Padda, MD, Stanford University Medical Center, Stanford CA
Elcin Zan, MD, New York University Grossman School of Medicine, New York, NY